Last reviewed · How we verify
Diclofenac sodium topical solution 1.5%
Diclofenac sodium topical solution 1.5% is a marketed product developed by Winston Parris, MD, with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and the extended patent protection, which helps maintain a competitive edge. The primary risk is the eventual patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Diclofenac sodium topical solution 1.5% |
|---|---|
| Sponsor | Winston Parris, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bonipar for Acute and Chronic Musculoskeletal Pain (PHASE2)
- Effects of Pennsaid on Clinical Neuropathic Pain (NA)
- Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel (PHASE1)
- Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac sodium topical solution 1.5% CI brief — competitive landscape report
- Diclofenac sodium topical solution 1.5% updates RSS · CI watch RSS
- Winston Parris, MD portfolio CI